✦ LIBER ✦

702 - 4-hydroxyandrostenedione (4-OHA) as third-line endocrine therapy in postmenopausal patients with advanced breast cancer

✍ Scribed by C.S. Gennatas; J. Psychogios; C. Dardoufas; N. Tsavaris; S. Athanasiadis

Book ID: 117664949
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 215 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85301-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Endocrinology and pharmacokinetics of or

Endocrinology and pharmacokinetics of oral 4-hydroxyandrostenedione in postmenopausal patients with advanced breast cancer [Poster 26]

✍ M. Dowsett; D. Cunningham; S. Nichols; A. Lal; S. Evans; A.M.H. brodle; S.L. Jef 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 148 KB

First-line endocrine therapy in postmeno

First-line endocrine therapy in postmenopausal (PM) patients (pts) with advanced breast cancer (ABC) and visceral metastases (mets): Anastrozole (AN) versus tamoxifen (TAM)

✍ I. Vergote; B. Thürlimann 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 184 KB

PP-8-4 An open, comparative randomized t

PP-8-4 An open, comparative randomized trial comparing formestane vs oral megestrol acetate as a second-line therapy in postmenopausal advanced breast cancer patients

✍ C. Rose; M. Freue; M. Kjaer; C. Boni; F. Jänicke; C. Coombes; P.H.B. Willemse; S 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Exemestane versus anastrozole as front-l

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer : Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

✍ Antonio Llombart-Cussac; Amparo Ruiz; Antonio Antón; Agustí Barnadas; Silvia Ant 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

‘Tomudex’ (raltitrexed) 4.0 mg/m[2] as s

‘Tomudex’ (raltitrexed) 4.0 mg/m[2] as second- or third-line therapy in patients with advanced colorectal cancer: a Phase II study

✍ A. Schulz; D. Garfield; W. Berry; D. Gordon; C. Lowery; M. Smith 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Randomized trial or the selective aromat

Randomized trial or the selective aromatase inhibitor formestane (Lentaron®) versus tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer

✍ R. Peréz-Carrion; V. Alberola; F. Calabresi; R-Th. Michel; R. Santos; M. Fehling 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 298 KB